Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19782890 | 0.90 | GPR35 (0.35) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19783548 | 0.90 | NR1D1 (0.32) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19783079 | 0.89 | PKM (0.36) | SMN1; SMN2NR1D1MAPT | |
| SCHEMBL18424588 | 0.88 | PDGFRB (0.37) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL21407959 | 0.87 | GPR35 (0.35) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19783383 | 0.82 | MAPT (0.33) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL18424786 | 0.80 | GPR35 (0.41) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19775901 | 0.78 | PDGFRB (0.42) | NPC1RAB9AGPR35HTTNR1D1 | |
| SCHEMBL21942179 | 0.77 | LMNA (0.36) | SMN1; SMN2HTTNR1D1MAPT | |
| SCHEMBL21379659 | 0.76 | GPR35 (0.40) | NPC1NFKB1RAB9ANFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-109689642-B | Monocyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3484874-B1 | MONOCYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018013772-A1 | MONOCYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | NPC1 2194/4885NFKB1 2579/4885RAB9A 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.